ADI responds to results of EXPEDITION3 study by Eli Lilly

23 November 2016 - Alzheimer’s Disease International (ADI) has noted the announcement of Phase 3 clinical trial results today that suggest negative results of the drug solanezumab by Eli Lilly. [read more]

ADI statement on rights of older persons in Latin America and the Caribbean

17 November 2016 - ADI Regional Representative to International Organizations, Raymond Jessurun, will deliver a statement today to the ECLA Expert Meeting on the Charter of San Jose on the Rights of Older people in Latin America and the Caribbean in Santiago de Chile. [read more]

National Plan launched in Argentina

09 November 2016 - The government of Argentina launched the National Strategic Plan for a Healthy Brain, Alzheimer's Disease and other Dementias on the 9 November 2016. The plan was developed by the Department of Social Services (PAMI) and Ministry of Health with the support of Alzheimer's Disease International (ADI) and the Alzheimer Association Argentina (ALMA). [read more]

Syndicate content